FOR IMMEDIATE RELEASE

AMNEAL RECEIVES FDA APPROVAL FOR OVER-THE-COUNTER STRENGTH NAPROXEN SODIUM TABLETS & CAPLETS, USP

Hauppauge, NY (USA), December 18, 2008 – Amneal Pharmaceuticals is pleased to announce that it has received US FDA approval to manufacture Naproxen Sodium Tablets and Caplets, USP 220 mg strength, an over-the-counter (OTC) product, effective December 18, 2008. Naproxen Sodium 220mg compares to the active ingredient in Aleve® (a trademark of Syntex Laboratories), indicated for the temporary relief minor aches and pains and temporary reduction of fevers.

This OTC strength naproxen sodium approval is well aligned with Amneal's strategic approach to its OTC portfolio as it leverages already strong production volumes of prescription strength naproxen sodium. In addition, the combined offering of OTC strengths of naproxen sodium, ibuprofen and docusate sodium enables Amneal to provide strong value to its current and potential OTC customers.

Amneal will begin shipping the Naproxen Sodium 220 mg Tablets and Caplets as of December 22, 2008 and will have the product available through private label companies, repackagers and some distributors as well as directly to the trade. There is strong demand for this product to date and Amneal expects its group of OTC products to be a significant growth area for 2009.

Amneal Pharmaceuticals LLC, headquartered in Paterson, NJ, is a USA-based firm that develops, manufactures and distributes generic pharmaceutical products regulated and approved by the US FDA. Positioned as "Generic's New Generation," the company utilizes diverse R&D and manufacturing expertise to conceive breakthrough developments with lasting impact. Vigorous ANDA growth and broad product acquisitions are key features of Amneal's strategic growth plan, as is the company's commitment to building deep relationships with its customer base. Amneal delivers superior service levels, quality products, and dynamic value throughout the pharmaceutical industry.

###

CONTACT: Jim Luce, Executive Vice President-Sales & Marketing
Amneal Pharmaceuticals, LLC
Direct: 949-610-8018
Mobile: 949-633-2293
Fax: 949-610-8218
E-mail: jim@amneal.com
www.amneal.com
Corporate Headquarters
85 Adams Avenue
Hauppauge, NY 11788